These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. Patil PD; Burotto M; Velcheti V Expert Rev Mol Diagn; 2018 Mar; 18(3):297-305. PubMed ID: 29430978 [TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Kumar P; Saini S; Prabhakar BS Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481 [TBL] [Abstract][Full Text] [Related]
6. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis. Berner F; Flatz L Immunol Rev; 2023 Sep; 318(1):37-50. PubMed ID: 37548043 [TBL] [Abstract][Full Text] [Related]
7. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963 [TBL] [Abstract][Full Text] [Related]
8. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Young A; Quandt Z; Bluestone JA Cancer Immunol Res; 2018 Dec; 6(12):1445-1452. PubMed ID: 30510057 [TBL] [Abstract][Full Text] [Related]
9. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210 [TBL] [Abstract][Full Text] [Related]
11. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733 [TBL] [Abstract][Full Text] [Related]
12. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647 [TBL] [Abstract][Full Text] [Related]
13. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Weinmann SC; Pisetsky DS Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080 [TBL] [Abstract][Full Text] [Related]
15. Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival. McGonagle D; Bragazzi NL; Amital H; Watad A Autoimmun Rev; 2020 Feb; 19(2):102456. PubMed ID: 31838166 [TBL] [Abstract][Full Text] [Related]
16. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS; J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153 [TBL] [Abstract][Full Text] [Related]
17. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. von Itzstein MS; Khan S; Gerber DE Clin Chem; 2020 Jun; 66(6):779-793. PubMed ID: 32363387 [TBL] [Abstract][Full Text] [Related]
18. Testing Immune-Related Adverse Events in Cancer Immunotherapy. Farmer JR Clin Lab Med; 2019 Dec; 39(4):669-683. PubMed ID: 31668277 [TBL] [Abstract][Full Text] [Related]